Lymphoma, Large-Cell Withdrawn Phase 2 Trials for Iratumumab (DB05550)

Also known as: Large-cell Lymphoma

IndicationStatusPhase
DBCOND0030182 (Lymphoma, Large-Cell)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00298467MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell LymphomaTreatment